Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies
Authors
Charles W Lynde (ORCID: https://orcid.org/0000-0001-9163-5463)
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies
Charles W Lynde, B. Geng, Grace K. W. Wong, Haobo Ren et al.
Journal
Dermatology and Therapy
Topics
Dermatology and Skin Diseases
article
Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 Studies
Charles W Lynde, B. Geng, Grace K. W. Wong, Haobo Ren, Daniel Sturm, Parbeer Singh Grewal, Howard Kallender, Dilan Paranagama, Andrew Blauvelt, Eric L. Simpson, Peter Lio, Lawrence F. Eichenfield, H. Chih-ho Hong, Leon Kircik, Vimal H. Prajapati
article en
Abstract
No abstract available for this paper.
Publication Tag
Dermatology and TherapyVol. 16(3)
Institutions
Northwestern University (US), University of British Columbia (CA), Oregon Health & Science University (US), University of Calgary (CA), Covenant Health (CA), University of California San Diego (US), SKiN Health (CA), Rady Children's Hospital-San Diego (US), Lynde Centre for Dermatology (CA), Maryland Department of Natural Resources (US), Probity Medical Research (CA), Oregon Medical Research Center (US), Aptose Biosciences (Canada) (CA), Indiana University School of Medicine, Indiana University – Purdue University Indianapolis (US), Incyte (United States) (US), Icahn School of Medicine at Mount Sinai (US)
Funders
Bristol-Myers Squibb, National Eczema Association, Eli Lilly and Company, Pfizer, Sanofi, Celgene, Regeneron Pharmaceuticals, Valeant Pharmaceuticals International, Incyte, Kyowa Hakko Kirin, Galderma, LEO Pharma, Sanofi Genzyme